Drug, bio-affecting and body treating compositions inventions 01/07

20070021321 - Method of screening drug with the use of 67 kda laminin receptor and drug obtained thereby: It is intended to provide a novel method of screening a drug with the use of a 67 kDa laminin receptor and a drug obtained thereby. A method of screening a drug having an effect on inhibiting cell proliferation, an angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis,... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070021324 - Process for preparation of mixtures of polypeptides using purified hydrobromic acid: The subject invention provides an improved process for obtaining a mixture of polypeptides having nonuniform amino acid sequences, where each polypeptide consists essentially of alanine, glutamic acid, tyrosine and lysine where the resulting mixture of polypeptides comprises less than 0.3% brominated tyrosine and less than 1000 ppm metal ion impurities.... Agent: Cooper & Dunham, LLP

20070021322 - Selective resonance of chemical structures: Chemical compositions may be selectively or preferentially excited by the application of scores comprising a series of energy inputs.... Agent: Searete LLC Suite 110

20070021323 - Use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer: e

20070021326 - Composition and its therapeutic use: A composition having a variety of therapeutic and cosmetic uses comprises: (i) a vitamin; (ii) a metal salt that provides metal ions in vivo; and (iii) insulin or a growth hormone. Such a composition is useful for treating, for example, genetic disorders, skin diseases, cancer and viral infections.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070021325 - Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability: Solubility, absorption, and permeability of drugs upon oral administration are improved when the drugs are mixed and/or complexed with water-miscible organic solvents. Illustratively, the absorption of a heparin-deoxycholic acid conjugate upon oral administration is increased by mixing and/or complexing this conjugate with dimethyl sulfoxide. Other illustrative water-miscible organic solvents include... Agent: Alan J. Howarth

20070021327 - Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor: A method is provided for treating solid tumors comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent. In a preferred embodiment the PDGF aptamer is identified using the SELEX process for the Systematic Evolution of Ligands by Exponential enrichment. A method is also provided for reducing the... Agent: Swanson & Bratschun L.L.C.

20070021328 - Semi-synthetic rearranged vancomycin/desmethyl-vancomycin-based glycopeptides with antibiotic activity: Semi-synthetic glycopeptides that have antibacterial activity are based on modifications of a rearranged vancomycin or desmethyl-vancomycin scaffold, in particular, alkylation or acylation of the amino substituent on the amino-substituted sugar moiety on this scaffold with certain acyl groups; and/or conversion of the acid moiety on the macrocyclic ring of this... Agent: Novartis Vaccines And Diagnostics Inc.

20070021330 - Aza-peptide macrocyclic hepatitis c serine protease inhibitors: The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus... Agent: Edwards & Angell, LLP

20070021331 - Methods of using macrocyclic modulators of the ghrelin receptor: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin... Agent: Myers Bigel Sibley & Sajovec

20070021329 - Treatment of hypersensitivity conditions: This invention relates to methods of treatment of hypersensitivity conditions such as asthma and other allergic conditions, and especially to treatment of these conditions with cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists of the... Agent: Haynes And Boone, LLP

20070021335 - Agent for improving mental disorders: The present invention provides an agent for improving mental disorders due to cerebral dysfunction and an agent for inhibiting vascular hyperpermeability each containing a hepatocyte growth factor. The agent for improving mental disorders according to the present invention is useful in improving mental disorders, particularly decline in learning and memory... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070021334 - Class iii slrp agonists for the reduction of blood vessel formation: The invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the inhibition of blood vessel formation. In addition the invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a... Agent: Michael Best & Friedrich, LLP

20070021339 - Glp-1 pharmaceutical compositions: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues.... Agent: Brian R. Morrill, Esq. Biomeasure Incorporated

20070021332 - Helminth-derived antigens having capacity of providing protection against parasites: The primary objective of the present invention is the development of new mutant forms of the Sm14 protein, for producing a greater production volume. The recombinant proteins here obtained were capable of providing protection against schistosome and fasciola infection. The level of protection of Sm14 recombinant proteins obtained in the... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20070021337 - Novel agent for inducing apoptosis comprising msx1 or a gene encoding the same as an active ingredient: The present invention relates to a novel use of Msx1 protein or a nucleotide encoding the same for inducing apoptosis. The Msx1 of the present invention induces apoptosis through direct interaction with p53 via a homeodomain and such interaction leads to increased stability, and/or nuclear localization of p53 in cells.... Agent: Sheridan Ross Suite 3500

20070021333 - Pharmaceutical compositions based on anticholinergics and soluble tnf receptor fusion proteins: The present invention relates to novel pharmaceutical compositions based on anticholinergics and soluble TNF receptor fusion proteins, processes for preparing them and their use in the treatment of respiratory diseases.... Agent: Edell, Shapiro & Finnan, LLC

20070021338 - Stabilised compositions of factor vii: The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these compositions can be stored, handled and used at room temperature.... Agent: Novo Nordisk, Inc. Patent Department

20070021343 - Stabilized teriparatide solutions: A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol... Agent: Eli Lilly & Company

20070021344 - Stabilized teriparatide solutions: A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH (1-34), mannitol, an acetate or tartrate buffering agent and... Agent: Eli Lilly & Company

20070021341 - Treatment of autoimmune conditions with copolymer 1 and related copolymers: The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one... Agent: Cooper & Dunham, LLP

20070021340 - Use of blood coagulation factor xiii for treating hemophilia a: A patient having hemophilia A is treated by administering factor XIII generally in conjunction with factor VIII or desmopressin.... Agent: Novo Nordisk, Inc. Patent Department

20070021336 - Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis: The present invention relates generally to the novel use of GLP-1, including analogs, and agonists, to prevent cardiac myocyte apoptosis. The present invention relates to methods for using GLP-1 for the treatment of conditions associated with cardiac myocyte apoptosis. The present invention further relates to improving the efficiency of cardiac... Agent: Arnold & Porter LLP (18528) Attn IPDocketing Dept.

20070021342 - Wound healing: Methods for accelerating and/or improving wound healing in a subject by administering vascular endothelial growth factor (VEGF) are provided.... Agent: Genentech, Inc.

20070021345 - Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases: Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X-Y or Y-X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such... Agent: Martin D Moynihan Prtsi Inc

20070021346 - Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases: The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The described compounds include chemically modified peptides that not... Agent: Louis J. Wille Bristol-myers Squibb Company

20070021348 - Novel treatment: A method of screening compounds to identify those compounds which inhibit the Asp 2 mediated cleavage of a polypeptide or protein substrate, the method comprising: providing a reaction system comprising Asp 2 and substrate; and measuring the extent of cleavage of the substrate in the presence of test compound as... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070021347 - Treatment for tumors: Where it was generally thought that the smallest breakdown products of proteins had no specific biological function on their own, it now emerges that the body may utilize the normal process of proteolytic breakdown to generate important compounds such as gene-regulatory or anti-tumor compounds. Such anti-tumor compounds are useful for... Agent: Trask Britt

20070021350 - Conjugates useful in the treatment of prostate cancer: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by attachment of the cleavable oligopeptide to the oxygen atom at the 4-position on a vinca drug... Agent: Merck And Co., Inc

20070021349 - Orthogonally protected bifunctional amino acid: The present invention concerns novel orthogonally protected amino acids, there production and use for the synthesis of binding compounds usable in the diagnosis and treatment of proliferative diseases, in particular tumor diseases.... Agent: Millen, White, Zelano & Branigan, P.C.

20070021351 - Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor: Compositions and therapeutic combinations are provided including at least one compound selected from the group consisting of compounds of Formulae I to XXVI as defined herein as well as methods of treatment, prevention or amelioration of one or more symptoms of hepatitis C, treating disorders associated with HCV virus, modulating... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070021352 - Prevention and treatment of hearing disorders: Compositions, and methods of use thereof, are provided for the prevention, treatment or alleviation of symptoms of hearing are provided. Embodiments of the methods employ zonisamide as the sole active pharmaceutical agent or a combination of zonisamide and another pharmaceutical agent, such as an antioxidant, a NMDA antagonist, an SSRI... Agent: Wilson Sonsini Goodrich & Rosati

20070021353 - Alpha ketoamide compounds as cysteine protease inhibitors: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.... Agent: Townsend And Townsend And Crew, LLP

20070021354 - Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing... Agent: Fitzpatrick Cella Harper & Scinto

20070021355 - Antidepressants or foods and beverage for antidepression: (wherein R1, R2, R3 and R4, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, or the like; R5 represents a hydrogen atom, hydroxy, or the like; R6 represents a hydrogen atom, or the like; R7 represents a hydrogen atom or substituted... Agent: Antonelli, Terry, Stout & Kraus, LLP

20070021356 - Preemptive prophlyaxis of migraine: A method of preventing the headache phase of migraine in a human comprises administration of an anti-convulsant medication to said human exhibiting prodrome symptoms of migraine. Suitably, the method comprises administration of a migraine headache phase-preventing effective amount of the anti-convulsant. There is also disclosed a pharmaceutical composition for the... Agent: Husch & Eppenberger, LLC

20070021357 - Treatment of inflammatory conditions: The invention relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070021358 - Localized delivery of cardiac inotropic agents: The present invention provides novel methods for the localized delivery of inotropic agents to the heart, including specific regions of the heart, such as the ventricles, for example in a subject undergoing cardiothoracic surgery, with the aim of supporting the myocardial contractile function of the heart.... Agent: Ronald I. Eisenstein Nixon Peabody LLP

20070021359 - Addition salts of azithromycin and citric acid and process for preparing them: Said addition salts have a molar ratio between azithromycin and citric acid such as to provide a pH comprised between 4.0 and 8.0 in a 10% aqueous solution. The process for preparing said salts comprises: a) dissolving azithromycin in a solvent or mixture of solvents; b) adding citric acid; and... Agent: Wolf Block Schorr And Solis-cohen LLP

20070021362 - Antisense antibacterial method and compound: A method and antisense compound for inhibiting the growth of pathogenic bacterial cells are disclosed. The compound contains no more than 12 nucleotide bases and has a targeting nucleic acid sequence of no fewer than 10 bases in length that is complementary to a target sequence containing or within 10... Agent: Perkins Coie LLP

20070021360 - Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase: A pharmaceutical composition and formulations comprise preventative, prophylactic or therapeutic amounts of an oligo(s) anti-sense to a specific gene(s) or its corresponding mRNA(s), and a glucocorticoid and/or non-glucocorticoid steroid or a ubiquinone or their salts. The agents, composition and formulations are used for treatment of ailments associated with impaired respiration,... Agent: Wilson Sonsini Goodrich & Rosati

20070021375 - Genetic modification of targeted regions of the cardiac conduction system: Disclosed are compositions, methods and systems for preventing or treating cardiac dysfunction, particularly cardiac pacing dysfunction by genetic modification of cells of targeted regions of the cardiac conduction system. In particular, a bio-pacemaker composition is delivered to cardiac cells to increase the intrinsic pacemaking rate of the cells, wherein the... Agent: Medtronic, Inc.

20070021363 - Genomic replacement therapy: Genomic Replacement Therapy uses the human genome found in mantle dentin of a patient's tooth to affect other cells of the body. Mantle Dentin cells in the developed tooth do not reproduce, therefore the DNA is “younger”. Replacing the genome with a “younger” one will hopefully create beneficial effect to... Agent: John M. Pavelchik

20070021365 - Inhibition of lysyl oxidase for treating tumor growth and diagnostics relating thereto: Disclosed are methods of identifying lysyl oxidase inhibitors and the use of such inhibitors to prevent and treat tumors, particularly metastatic tumors, alone and in combination with chemotherapeutic agents. Further disclosed is the use of lysyl oxidase levels for measuring metastatic potential and survival.... Agent: Peters Verny Jones & Schmitt, L.L.P.

20070021361 - Methods and materials for modulating trpm2: The invention relates to antisense oligonucleotides, compositions and methods useful for modulating the expression of TRPM2. The compositions comprise antisense oligonucleotides, particularly antisense oligonucleotides targeted to nucleic acids encoding TRPM2.... Agent: Fish & Richardson P.C.

20070021364 - Methods for genetic immunization: The present invention relates to methods for delivering a genetic immunogen, comprising a nucleic acid capable of expressing an antigen, optionally complexed with a polymer. The nucleic acid is delivered to the host via hydrodynamic intravascular injection resulting in expression of an encoded antigen in extravascular cells and induction of... Agent: Mirus Corporation

20070021367 - Modulation of socs-3 expression: Compounds, compositions and methods are provided for modulating the expression of SOCS-3. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SOCS-3. Methods of using these compounds for modulation of SOCS-3 expression and for diagnosis and treatment of disease associated with expression of SOCS-3 are provided.... Agent: Knobbe, Martens, Olson & Bear, LLP

20070021368 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070021369 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070021370 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070021371 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070021372 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070021373 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070021374 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070021366 - Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use: Provided herein is a crystallized ternary structure of aldose reductase (AR) bound to NADPH and γ-glutamyl-S-(1,2-dicarboxyethyl)cysteinylglycine (DCEG). Also provided are specific inhibitors of glutathione-aldehyde binding to aldose reductase which are designed via at least computer modeling of the ternary AR:NADPH:DCEG structure and methods of designing and of screening the inhibitors... Agent: Benjamin Aaron Adler Adler & Associates

20070021376 - Supplement composition and method of use in enhancement of methylation process: A supplement composition for enhancement of methylation process is provided, which contains vitamin B6 (as pyridoxine HCl), folic acid, vitamin B12 (as cyanocobalamin), betaine HCl, and methylsulfonylmethane; and also contains S-adenosylmethionine. The supplement composition further includes silymarin (from milk thistle seed extract), N-acetyl L-cysteine, and cruciferious blend which includes broccoli... Agent: Melvin K. Silverman

20070021377 - Pharmaceutical composition comprising a macrolide immunomodulator: Snyergistic combination of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33-desoxyascomycin and a ceramide such as ceramide 3, LPC-9S or linoleic acid are provided, which are useful in particular in the treatment of dermatological or mucosal diseases such as atopic or contact dermatitis or dry skin, asteatotic eczema or... Agent: Novartis Corporate Intellectual Property

20070021378 - Heparin compositions and selectin inhibition: The disclosure provides in vitro and in vivo methods for identifying Heparins and Heparinoids that modulate the activity of selecting. The disclosure also provides Heparins and Heparinoids that modulate the activity of selecting. The identification and isolation of these heparin formulations has the potential to mediate a wide variety of... Agent: Buchanan, Ingersoll & Rooney LLP

20070021379 - Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities: The present invention is directed to nicotinamide derivatives, and their use in treating lipoprotein abnormalities, alone or in combination with a statin.... Agent: Lahive & Cockfield, LLP

20070021380 - Novel drug delivery compositions: The present invention provides for a novel molecules useful for delivery of compounds to a mammal, more particularly for the intracellular delivery of nucleotides, nucleotide analogues or compounds with a heterocyclic base. Also provided for are novel therapeutic complexes comprising novel molecules complexed with nucleotide analogues or heterogeneous or homogenous... Agent: Craig K. Sherbume

20070021381 - Method for increasing the activity of lysosomal enzymes: Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance the activity of the enzyme. Preferred compounds for use in the method are imino sugars and related compounds. In particular, C8-12-alkyl... Agent: Baker & Botts L.L.P.

20070021386 - Azole derivatives and fused bicyclic azole derivatives as therapeutic agents: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20070021385 - Compositions and methods for wood preservation: Provided is a composition and method for the preservation of wood. The composition comprises 1) an azole and/or quaternary ammonium compound component and 2) a pyrethroid compound component such that wood treated with the composition has a greater decay resistance than wood treated to the same azole retention with the... Agent: Hodgson Russ LLP

20070021384 - Compounds for use in the treatment of infection: in which each of R8 to R10 is hydrogen, aryl, C1-6 alkyl, trialkylsilyl or acyl; R1 to R5 are individually selected from hydrogen, hydroxy, C1-6 alkoxy and acyloxy; R6 and R7 are H, C1-4 alkyl, trialkylsilyl or acyl; X is O or NR, and R is H or Me; in... Agent: Oliff & Berridge, PLC

20070021382 - Nitric oxide donors and uses thereof: Disclosed are novel NO-donating compounds, designed such that when NO is released from the compound a residue which is a naturally occurring metabolite is formed, and thus a development of tolerance to the compounds upon repetitive administration is prevented or decreased. Also disclosed are methods of preparing such NO-donating compounds,... Agent: Martin Moynihan Prtsi Inc

20070021383 - Organosilane quaternaries for acaricidal activity: A method for killing acarids on a surface is disclosed. The method includes applying a solution comprising an organosilane quaternary compound to the surface such that the surface is wet. In one example, the compound comprises an organosilane quaternary such as 3-(trimethoxysilyl)propyldimethyloctadecyl ammonium chloride. In another example, the solution further... Agent: Richard S. Ross, Esq.

20070021387 - Florfenicol prodrug having improved water solubility: The present invention discloses phosphate esters of florfenicol (prodrugs) and florfenicol analogs having superior water solubility that are hydrolyzed to florfenicol or the respective florfenicol analog in vivo, upon administration to an animal.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070021388 - Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs: wherein: V and L are trans relative to one another; V is selected from group consisting of carbocyclic aryl, substituted carbocyclic aryl, heteroaryl, and substituted heteroaryl; and L is a leaving group selected from the group consisting of halogen, alkyl sulfonate, aryloxy optionally substituted with 1-2 substituents, N-containing heteroaryl, and... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070021389 - Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation: The invention relates to polymorphs of zoledronic acid and zoledronate sodium salts, amorphous zoledronate sodium salt, processes for making the polymorphs and amorphous zoledronate sodium salt, and pharmaceutical compositions containing the polymorphs and amorphous zoledronate sodium salt.... Agent: Kenyon & Kenyon LLP

20070021390 - Derivatives of heterocycles with 5 members, their preparation and their use as medicaments: e

20070021392 - Divided dose therapies with vascular damaging activity: The invention concerns the use of a vascular damaging agent or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for administration in divided doses for use in the production of a vascular damaging effect in a warm-blooded animal such as a human. In particular the vascular damaging... Agent: Morgan Lewis & Bockius LLP

20070021393 - New use of gabab receptor agonists: e

20070021391 - Preventive/remedy for urinary disturbance: It is intended to provide a preventive/remedy for urinary disturbance containing a compound, which shows an acetylcholine esterase inhibitory activity but substantially has no butyrylcholine esterase inhibitory activity, showing no side effect and being safe and efficacious without inhibiting the urine collection function; a preventive/remedy for dry mouth induced by... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070021394 - 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative: [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a... Agent: Sughrue Mion, PLLC

20070021395 - Compositions for reducing the incidence of drug induced arrhythmia: In accordance with the present invention, novel methods and formulations are provided for treating and preventing the incidence of drug-induced pro-arrhythmia, including torsades de pointes. The methods and formulations comprise a combination of a drug that induces torsade de pointes, such as Class III antiarrhythmics, certain antimicrobials, antihistamines, antidepressants, antipsychotics,... Agent: The Procter & Gamble Company Intellectual Property Division

20070021396 - Oral contraception with trimegestone: The invention relates to a method for contraception comprising the administration of trimegestone to a woman of child-bearing age on at least 21 successive days, beginning on day 1 of the menstrual cycle, wherein on at least one of the at least 21 successive days the daily dose of trimegestone... Agent: Perman & Green

20070021399 - Amido-amino alcohols as therapeutic compounds: e

20070021400 - Amino alcohols as therapeutic compounds:

20070021397 - Neurocyte protective agent: A protective agent for neurons of the central nervous system and a prophylactic and/or therapeutic agent for disorders in neurons of the central nervous system is provided, each including a compound represented by donepezil hydrochloride.... Agent: Darby & Darby P.C.

20070021398 - Substituted pyrazoline compounds, their preparation and use as medicaments: The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.... Agent: Banner & Witcoff

20070021401 - Metal complexes of n-heterocyclic carbenes as radiopharmaceuticals and antibiotics: e

20070021402 - Novel oral pharmaceutical suspension of cefdinir crystal: The present invention relates to a novel oral pharmaceutical suspension of Cefdinir crystal. More specifically, the present invention relates to a novel kit for preparation of an oral pharmaceutical suspension containing crystal form C Cefdinir.... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070021405 - Aryl- and heteroarylpiperidinecarboxylate-derivatives methods for their preparation and use thereof as fatty acid amido hydrolase enzyme inhibitors: in which m, n=1 to 3 and m+n=2 to 5; p=1 to 7; A=single bond or X, Y and/or Z; X=optionally substituted methylene; Y=C2-alkenylene, which is optionally substituted, or C2-alkynylene; Z=C3-7-cycloalkyl; R1 represents a group of aryl or heteroaryl type; R2 represents a hydrogen or fluorine atom or a hydroxyl,... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070021404 - Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: This invention relates to novel aza-ring derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Birch Stewart Kolasch & Birch

20070021403 - Piperidinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase enzyme inhibitors: The present invention comprises peridinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase (FAAH) enzyme inhibitors. These derivatives exert various pharmacological activities by interacting, inter alia, with cannabinoid and vanilloid receptors. By inhibiting the metabolic activity of the FAAH enzyme, compounds often responsible... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070021406 - New neurokinin antagonists for use as medicaments: The present application relates to internally cyclized naphthamide compounds of the formula Ia (wherein R1a, R1b, R1c, R2, R3, R4, R5, R6, R7, R8, X1, X2, Y, Z, and n are as defined herein), which are useful, for example, for antagonizing the pharmacological actions of the neurokinin 1 (NK1) receptor.... Agent: Cozen O'connor, P.C.

20070021407 - Substituted quinolines as antitumor agents: (v) a group of the formula —X1—C1-3alkyl-CO—NR18NR18—R20 where R18 is as defined above and R20 is selected from hydrogen or C1-5alkoxycarbonyl; or (vi) a heterocyclic ring. The invention also provides a process for the preparation of a compound of Formula (Ia), pharmaceutical compositions of a compound of Formula (Ia) and... Agent: Morgan Lewis & Bockius LLP

20070021408 - Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin: )

20070021409 - Antiparasitic artemisinin derivatives (endoperoxides): This invention relates to the use of certain C-10 substituted derivatives of artemisinin of general formula (I) in the treatment and/or prophylaxis of diseases caused by infection with a parasite, certain novel C-10 substitued derivatives of artemisinin, processes for their preparation and pharmaceutical compositions containing such C-10 substituted derivatives. The... Agent: Jeffrey M. Greenman

20070021410 - Respiratory syncytial virus replication inhibitors: This invention concerns the use of compounds of formula (I) wherein -a1=a2-a3 =a4- is a radical of formula —CH═CH—CH═CH—, —N═CH—CH═CH—, —CH═N—CH═CH—, —CH═CH—N═CH—, —CH═CH—CH═N— wherein each hydrogen atom may optionally be substituted; Q is a radical of formulas (b-1), (b-2), (b-3), (b-4), (b-5), (b-6), (b-7), (b-8). G is a direct bond... Agent: Woodcock Washburn LLP

20070021411 - Supersaturated benzodiazepine solutions and their delivery: The invention describes supersaturated solutions of benzodiazepines, such as diazepam, glycofurol and water and their use for intranasal (NS) administration to combat various disorders.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070021412 - Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (s) 2,3-benzodiazepine: The present invention relates to methods of treatment for symptoms of gastrointestinal dysfunction and related stress that are frequently associated with, for example, irritable bowel syndrome. The symptoms include altered bowel motility, gastrointestinal inflammation, visceral hypersensitivity, or gastric ulcers.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070021413 - Diamino alcohols as therapeutic compounds: e

20070021414 - 1-'2-(4-hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists: This invention provides a compound of the formula (I), wherein R1 and R2 independently represents a hydrogen atom or the like; R3 represents an aryl group having from 6 to 10 ring carbon or the like; said aryl groups having from 6 to 10 ring carbon atoms and said heteroaryl... Agent: Warner-lambert Company

20070021415 - Pharmaceutical composition for the prevention or treatment of cerebral oedemas: i

20070021416 - Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems. Formula I:... Agent: Elmore Patent Law Group, PC

20070021417 - Processes for the preparation of linezolid intermediate: The present invention provides improved methods of converting R-N-(4-morpholiyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl azide (III) to the intermediate S-N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) that involve the production of fewer by-products than previous methods. The amine (II) may then be converted into linezolid (I) of high chemical purity with respect to the inactive R-enantiomer and bis-linezolid (IV),... Agent: Kenyon & Kenyon LLP

20070021419 - 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors: e

20070021418 - Method of inhibiting production of osteopontin:

20070021420 - New derivatives of hydantoins, thiohydantoins, pyrimidinediones and thioxopyrimidinones, their preparation processes and their use as medicaments:

20070021421 - Measurement of gait dynamics and use of beta-blockers to detect, prognose, prevent and treat amyotrophic lateral sclerosis: The present invention, at least in part, provides methods of improved early diagnosis of neurodegenerative disease, e.g., ALS, in a subject via measurement of the gait dynamics of the subject (e.g., via the exemplary ventral plane videography methods disclosed herein). The present invention also provides for administration of a beta-adrenergic... Agent: Lahive & Cockfield, LLP

20070021424 - Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics: e

20070021423 - Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof: The invention relates to dual molecule compounds containing a peroxide derivative, to processes for the synthesis of such compounds, to pharmaceutical compositions comprising such compounds, and to methods of treatment and prevention of malaria comprising administering such compounds and such pharmaceutical compositions.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070021422 - Prokineticin 1 receptor: The present invention relates to methods of monitoring the biological activity of the PK1 receptor.... Agent: Philip S. Johnson Johnson & Johnson

20070021425 - Reverse-turn mimetics and method relating thereto: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed... Agent: Seed Intellectual Property Law Group PLLC

20070021426 - Derivatives of heteroaryl-alkylcarbamates, methods for their preparation and use thereof as fatty acid amido hydrolase enzyme inhibitors: n

20070021427 - Novel tricyclic derivatives and their use: The present invention relates to tricyclic colchicine derivatives represented by the formulas (I) or (II), pharmaceutically acceptable salts thereof, and a method for providing an immuno-suppressive or immuno-modulating effect, an anti-proliferative effect, an anti-inflammatory effect or a method for treating cancer comprising administering to a patient an effective amount of... Agent: Buchanan, Ingersoll & Rooney PC

20070021428 - Immunomodulating heterocyclic compounds: Compounds of formula (I) are inhibitors of CD80 and useful in immunomodulation therapy: wherein R1 and R3 independently represent H; F; CI; Br; —NO2; —CN; C1-C6 alkyl optionally substituted by F or Cl; or C1-C6 alkoxy optionally substituted by F; R4 represents a carboxylic acid group (—COOH) or an ester... Agent: Banner & Witcoff

20070021429 - Condensed n-heterocyclic compounds and their use as crf receptor antagonists: The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof (Formula (I)) wherein the dashed line may represent a double bond; R is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups J selected from: halogen, C1-C6... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070021430 - Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor: The present invention relates to a novel crystalline anhydrate polymorph of the dihydrogenphosphate salt of (2R)-4-oxo-4-[3-trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine as well as a process for their preparation, pharmaceutical compositions containing this novel form, and methods of use of the novel form and pharmaceutical compositions for the treatment of diabetes, obesity, and high blood... Agent: Merck And Co., Inc

20070021431 - Reverse-turn mimetics and method relating thereto: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed... Agent: Seed Intellectual Property Law Group PLLC

20070021432 - Treatment of mesothelioma: The present invention relates to a method of treating a warm-blooded animal, especially a human, having mesothelioma, especially malignant mesothelioma, comprising administering to said animal a therapeutically effective amount of a 4-pyridylmethyl-phthalazine derivative.... Agent: Novartis Corporate Intellectual Property

20070021433 - Pharmacological chaperones for treating obesity: The invention relates to methods of enhancing normal melanocortin-4 receptor (MC4R) activity, and to enhancing activity of an MC4R having a mutation which affects protein folding and/or processing of the MC4R. The invention provides a method of treating an individual having a condition in which increased activity of an MC4R... Agent: Baker & Botts

20070021434 - Non-nucleoside anti-hepacivirus agents and uses thereof: The present dislcosure provides amide-based, non-nucleoside compounds having antiviral activity against Hepacivirus, such as hepatitis C virus (HCV), methods and intermediates for synthesizing such compounds, and methods of using the compounds in a variety of contexts, including in the treatment and prevention of viral infections. The present dislcosure also provides... Agent: Darby & Darby P.C.

20070021435 - Aminopyrimidines as kinase modulators: where R3, B, Z, r and R1 are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or... Agent: Philip S. Johnson Johnson & Johnson

20070021436 - Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis: e

20070021437 - Substituted pyrazoles: Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S.... Agent: Philip S. Johnson Johnson & Johnson

20070021438 - Itraconazole solution: A solution for oral administration comprising itraconazole, an alcoholic solvent, and an acid.... Agent: Nixon & Vanderhye, PC

20070021440 - Inhibitors of macrophage migration inhibitory factor and methods for identifying the same: s

20070021439 - Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers: Prophylactic treatment methods are provided for protection of individuals and/or populations against infection from airborne pathogens. In particular, prophylactic treatment methods are provided comprising administering a sodium channel blocker or pharmaceutically acceptable salts thereof to one or more members of a population at risk of exposure to or already exposed... Agent: Hutchison Law Group PLLC

20070021441 - Fungicidal mixtures for fighting against rice pathogens: o

20070021442 - Hiv reverse transcriptase inhibitors: are HIV reverse transcriptase inhibitors, wherein A, X, Y, Z, R1 and R2 are defined herein. The compounds and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment... Agent: Merck And Co., Inc

20070021443 - Purine and imidazopyridine derivatives for immunosuppression: The present invention provides novel purine and imidazopyridine derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulas:... Agent: Heslin Rothenberg Farley & Mesiti PC

20070021444 - Valacyclovir polymorphs and a process for the preparation thereof: A process for the preparation of valacyclovir hydrochloride in monohydrate form, as well as of several other hydrate and anhydrous forms, and novel hydrate polymorphic forms obtainable by said process.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20070021445 - Pyridopyrimidine protein tyrosine phosphatase inhibitors: p

20070021446 - 2-arylbenzothiazole analogues and uses thereof:

20070021447 - 2-imino-4-(thio)oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors: The present invention is related to 2-imino-azolinone-vinyl fused-benzene derivatives of Formula (1) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070021448 - Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation: The present invention relates to a method of treating an inflammatory disorder in a subject with an effective amount of compound having the general formula (I) as described in the present application, under conditions effective to treat the inflammatory disorder. The present invention also relates to a method of inhibiting... Agent: Nixon Peabody LLP - Patent Group

20070021450 - Indanylamino uracils and their use as antioxidants and neuroprotectants: enantiomers, tautomers, and pharmaceutically acceptable salts of the compounds, pharmaceutical compositions containing such compounds or salts, and processes for their preparation. The subject invention also provides methods of alleviating symptoms of neurologic and inflammatory disorders, methods of preventing oxidation of lipids, proteins, or deoxyribonucleic acids on a cellular level, and... Agent: Cooper & Dunham, LLP

20070021451 - Method for preventing or treating neurologic damage after spinal cord injury: a

20070021449 - Pyrimidine derivatives for the prevention of hiv infection: This invention concerns the use of a compound for the manufacture of a medicament for the prevention of HIV infection via sexual intercourse and related intimate contact between partners, wherein the compound is a compound of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a... Agent: Philip S. Johnson Johnson & Johnson

20070021452 - Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy: i

20070021453 - Novel spirochromanone derivatives:

20070021454 - Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease: and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in... Agent: Merck And Co., Inc

20070021455 - Process for the preparation of finasteride form i: A process of preparing finasteride Form (I), which process comprises dissolving finasteride in a solvent, replacing the solvent partially or substantially completely with a nonsolvent and thereafter isolating finasteride Form (I). There is also provided finasteride Form (I) prepared in accordance with the present invention, and the therapeutic use thereof... Agent: Stevens Davis Miller & Mosher

20070021456 - Aminobenzimidazole derivatives: Novel compounds of formula (I) are disclosed, where R1, R1′, L, Y, m and p have the meanings given in claim 1, which are inhibitors of tyrosine kinases, in particular, TIE-2 and Raf kinases and can be used for the treatment of tumors.... Agent: Millen, White, Zelano & Branigan, P.C.

20070021457 - Large substituent, non-phenolic opioids: v

20070021458 - Selective resonance of bodily agents: Chemical compositions may be selectively or preferentially excited by the application of scores comprising a series of energy inputs.... Agent: Searete LLC Clarence T. Tegreene

20070021459 - Pyrazole derivatives and use thereof as orexin receptor antagonists: The present invention relates to the orexin receptor antagonists compounds of the general formula (I) as well as to their isomers, salts and solvates, to the pharmaceutical compositions containing them and to the therapeutic application thereof.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070021460 - Novel piperidine derivative: The present invention provides a piperidine derivative represented by the following formula or analogs thereto, which are used for agents for treating or preventing various diseases related to 5-HT7.... Agent: Nath & Associates

20070021461 - Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof: e

20070021462 - Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof:

20070021463 - Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives:

20070021464 - Methods and compositions for inhibition of angiogenesis with em-12 derivatives: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as EM-12 and its derivatives have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.... Agent: Jones Day

20070021465 - Anti-inflammatory compounds: Compounds of Formula (I), pharmaceutical compositions comprising compounds of Formulae (Ia) or (VII) and a method of treating a subject with an inflammatory cytokine-mediated disorder comprising administering to the subject a compound of Formulae (Ia) or (VIIa). The variables of Formulae (I), (Ia), (VII) and (VIIa) are described herein.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070021466 - Ccr2 inhibitors and methods of use thereof: Compounds are provided that act as potent antagonists of the CCR2 receptor. These compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for... Agent: Brinks Hofer Gilson & Lione

20070021467 - Salts of omeprazole and esomeprazole ii: The present invention relates to new salts of the single enantiomers of omeprazole, i.e. salts of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole ((S)-omeprazole) and (R)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole ((R)-omeprazole) respectively. More specifically, the present invention relates to 1-cyclohexylethyl ammonium salts of the compounds, formed by a reaction of (S)-omeprazole and (R)-omeprazole respectively and 1-cyclohexylethyl amine. The present invention... Agent: White & Case LLP Patent Department

20070021468 - Preparation and use of 2-substituted-5-oxo-3-pyrazolidinecarboxylates: A method is disclosed for preparing a 2-substituted-5-oxo-3-pyrazolidinecarboxylate compound of Formula I. The method comprises contacting a succinic acid derivative of the formula R1OC(O)C(H)(X)C(R2a)(R2b)C(O)Y (i.e. Formula II) wherein X and Y are leaving groups and L, R1, R2a and R2b are as defined in the disclosure, with a substituted hydrazine... Agent: David E Heiser E I Du Pont De Nemours And Company

20070021469 - Synthesis of nicotine derivatives from nicotine: Methods of synthesizing nicotine analogs and derivatives are described. In some embodiments the methods utilize an alkyl or aryl silyl-substituted nicotine analog intermediate. Intermediates useful for the synthesis of nicotine and nicotine analogs are also described.... Agent: Myers Bigel Sibley & Sajovec

20070021472 - Benzamides and related inhibitors of factor xa: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.... Agent: Foley & Lardner LLP

20070021471 - Crystalline n-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide ethanolates: Ethanolates of N-(2-((4-Hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide, ways to make them, compositions containing them or made with them, and methods of treating diseases using them or drugs made from them. are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20070021470 - Crystalline n-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide methanolates: Methanolates of N-(2-((4-Hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide, ways to make them, compositions containing them or made with them, and methods of treating diseases using them or drugs made from them are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20070021473 - Novel ligand activators of the rar receptors and pharmaceutical/cosmetic applications thereof: t

20070021474 - Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals:

20070021475 - Substituted triazole derivatives: R1, R2 and R3 are as defined in the specification and to pharmaceutically suitable acid addition salts thereof. The invention includes all sterioisomeric forms, including individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof. It has been found that the present... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070021476 - Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems. Formula I:... Agent: Elmore Patent Law Group, PC

20070021478 - Benzothiazolyl derivatives: i

20070021477 - Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes: The present invention is directed to novel cyclohexylglycine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also... Agent: Merck And Co., Inc

20070021480 - Biologically active compounds obtainable from sorangium cellulosum: The present invention relates to a novel group of compounds having antibiotic, antifungal and/or cytostatic properties, which are obtainable from myxobacteria, especially of the genus Sorangium, preferably Sorangium cellulosum. One representative of this group of compoundsis currently named Disorazole Z and Disorazole Z-epoxide, respectively, with specific substituents and specific unsaturated... Agent: William Collard Collard & Roe, P.C.

20070021479 - Phorboxazole compounds and methods of their preparation: Novel macrolactone compounds, their methods of preparation, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the macrolactone compounds may be useful, inter alia, for treating various cancers, inducing apoptosis in malignant cells, or inhibiting cancer cell division.... Agent: Woodcock Washburn LLP

20070021481 - Anti-androgenic pyrrolidines with tumor-inhibiting action: v

20070021482 - 1,5,7-trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex:

20070021483 - Amidine derivatives for treating amyloidosis: The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for... Agent: Lahive & Cockfield, LLP

20070021484 - Substituted n-cinnamyl benzamides: Substituted benzamide compounds are provided along with methods for the use of those compounds for treating cancer.... Agent: Townsend And Townsend And Crew, LLP

20070021485 - Aryl (or heteroaryl) azolylcarbinols: b

20070021486 - Derivatives of n-' (1,5-diphenyl-1h-pyrazol-3-yl) sulfonamide with cb1 receptor affinity:

20070021487 - Azabicyclo derivatives as muscarinic receptor antagonists: This invention generally relates to muscarinic receptor antagonists of formula (I) which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Specifically, the invention relates to derivatives of azabicyclo compounds, including, for example, 6-substituted azabicyclo[3.1.0]hexanes, as well... Agent: Ranbaxy Inc.

20070021488 - Method for treating nervous system disorders and conditions: i

20070021489 - Fibrinogen receptor antagonists and their use: wherein the symbols are defined herein, to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and to methods of using the compounds, alone or in combination with other therapeutic agents. The compounds are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, and are therefore useful for the... Agent: Volpe And Koenig, P.C.

20070021490 - Process for manufacture of pure (2s, 3as, 7as)-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl) butyl] amino]-1-oxopropyl] octahydro-1h-indole-2-carboxylic acid and its tert. butyl amine salt: New compounds useful as synthetic intermediates to synthesize perindopril, a new process for synthesizing perindopril, and new salts of perindopril.... Agent: Pharmaceutical Patent Attorneys, LLC

20070021491 - Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events: Use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin, in the manufacture of a medicament for the prevention of cardiovascular events; a method of preventing cardiovascular events comprising administering to a patient... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070021493 - Mediators of hedgehog signaling pathways, compositions and uses related thereto: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function by contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize hedgehog activity.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070021492 - Sulfamatet benzothiophene derivatives as steroid sulfatase inhibitors: The present invention relates to sulfamate benzothiophene compounds of the formula: (I) wherein R1, R2, R3, m and n are as defined in the specification. The invention also relates to pharmaceutical compositions containing these compounds and to methods of using them.... Agent: Dennison, Schultz & Macdonald

20070021494 - 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands: e

20070021495 - Sulfonamides as selective estrogen receptor:

20070021496 - Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass: The present invention relates to improved diagnostic methods for early detection of a risk for developing an arthritic disorder in humans, and screening assays for therapeutic agents useful in the treatment of arthritic disorders, by comparing the levels of one or more indicators of altered mitochondrial function. Indicators of altered... Agent: Seed Intellectual Property Law Group PLLC

20070021497 - Vitamin e compositions: A Vitamin E composition containing tocotrienols (alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, and delta-tocotrienol), and tocopherols comprising at least alpha-tocopherol and gamma-tocopherol, where the gamma-tocopherol is present in an amount greater than the alpha-tocopherol. The composition may take the form of any conventional delivery mechanism, with softgel capsules being a preferred form.... Agent: Patent Group Attn: J. Kenneth Joung

20070021498 - Novel tricyclic spiroderivatives as modulators of chemokine receptor activity: The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, Z, R3, R4, R5, R6, R7, R8, t and R9 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Fish & Richardson P.C.

20070021499 - Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base: The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a... Agent: Darby & Darby P.C.

20070021500 - Methods for neuroprotection: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with... Agent: Philip S. Johnson Johnson & Johnson

20070021501 - Methods of treating epileptogenesis: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with... Agent: Philip S. Johnson Johnson & Johnson

20070021502 - Aniline sulfonamide derivatives and their uses: e

20070021503 - Ophthalmic fluid: An ophthalmic fluid containing at least one triglyceride, diglyceride, or monoglyceride which is chemically similar or compatible with compounds found naturally in the lipid layer of the tear film of an ocular substrate. Preferably the glycerides are derived from a fatty acid containing at least one unsaturated bond in a... Agent: Duane Morris, LLPIPDepartment

20070021504 - Composition and/or method for preventing onset and/or recurrence of cardiovascular events: Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI.... Agent: Birch Stewart Kolasch & Birch

20070021505 - Prevention and treatment of ophthalmic complications of diabetes: An method and formulation are provided for the prevention and treatment of adverse ocular conditions which are complications of diabetes. In one embodiment, the invention comprises administering to a person having diabetes, insulin resistance, or a risk factor for diabetes a formulation comprising a metal chelator and a transport enhancer.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20070021506 - Stress relieving composition: A composition for relieving stress and/or disorder caused by stress is provided, which composition comprises lysine and arginine as active ingredients. The lysine and arginine may be in the form of a salt. In a preferred mode, the cause of stress is any one selected from the group consisting of... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070021507 - Aqueous eye drops with accelerated intraocular migration: An aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof and an organic amine (for example, aminoethylsulfonic acid or trometamol) or a salt thereof is useful as an eye drop for once a day administration for treating inflammatory diseases of the external segment or... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070021508 - Method for treatment of helicobacter pylori infection and/or an associated disease: in which R1 and R2, independently, are C1-C8alkyl or H, R3 is aryl or heteroaryl, and n is 0, 1, 2, 3, 4, 5 or 6. The present invention also relates to a method for treatment of Helicobacter pylori (HP) infection or disease associated with HP infection by administering a... Agent: Andrews Kurth LLP

20070021509 - Phosphate transport inhibitors: or a pharmaceutically acceptable salt thereof. Ar1 and Ar2 are independently a substituted or unsubstituted aryl group or an optionally substituted five membered or six membered non-aromatic heterocylic group fused to an optionally substituted monocylic aryl group. W and Y are independently a covalent bond or a C1-C3 substituted or... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070021510 - Modafinil compositions: Co-crystals and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and several important physical properties are modulated. The solubility, dissolution, bioavailability, dose response, and stability of modafinil can be modulated to improve efficacy in pharmaceutical compositions.... Agent: Cephalon, Inc.

20070021511 - Composition comprising phytosphingosine or a derivative thereof: Provided is a composition for cancer treatment including phytosphingosine or a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.... Agent: Cantor Colburn, LLP

20070021512 - Inhibition of the raf/mek/p-erk pathway for treating cancer: The invention disclosed herein provides for methods of treating cancer using inhibitors of the Raf/Mek/P-Erk 1/2 pathway. These inhibitors include B2AR agonists (such as ARA-211 (pirbuterol) and isoproterenol), adenylyl cyclase activators, cAMP analogs and Epac activators. The invention also provides methods for diagnosing cancer in an individual.... Agent: Morrison & Foerster LLP

20070015685 - Bone cement compositions and the like comprising an rnaiii-inhibiting peptide: RNAIII-inhibiting peptide (RIP) advantageously treats or reduces the risk of biofilm formation on implanted bone cement, thus reducing the possibility of sustained chemotherapy, hospitalization, or surgical removal of the bone cement. Unlike antibiotics, RIP eradicates biofilms without inducing resistant bacterial strains, making RIP particularly advantageous in this application. Biodegradable compositions... Agent: Merchant & Gould PC

20070015686 - Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells: A dietary supplement and method for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells an individual, the supplement comprising at least source of Creatine or derivatives thereof, a source of Gypenosides or Phanoside or derivatives thereof, Creatinol-O-phosphate, and a... Agent: Kenyon & Kenyon LLP

20070015687 - Synergistic pharmaceutical combination for the prevention or treatment of diabetes: The invention refers to a synergistic pharmaceutical combination which comprises (a) a first pharmaceutical composition containing an antidiabetic or anti-hyperlipidemic active agent and one or more conventional carrier(s), and (b) a second pharmaceutical composition containing a hydroximic acid derivative of the formula I and one or more conventional carrier(s). The... Agent: Birch Stewart Kolasch & Birch

20070015689 - Complexation of metal ions with polypeptides: Formulations and methods are provided for improving the stability upon exposure to aqueous media of polypeptides present in non-aqueous suspension vehicles. In particular aspects of the invention, formulations are provided that comprise a complex of a metal ion and a polypeptide suspended in a non-aqueous, biocompatible suspension vehicle. Aggregation of... Agent: Woodcock Washburn LLP

20070015688 - Method for screening for inhibitors of alzheimer's disease: This invention relates to compounds which have the ability to act as agonists for the binding of divalent copper ions to amyloid precursor protein (APP) and to methods of identifying such compounds by using the three-dimensional structure of the copper-binding domain of APP.... Agent: Leopold Presser Scully Scott Murphy & Presser

20070015690 - Cyclosporin compositions: A composition comprising from about 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein.... Agent: Allergan, Inc.

20070015691 - Cyclosporin compositions: A composition is disclosed herein comprising from about 0.001% to about 0.4% cyclosporin A, castor oil, and a surfactant selected from the group consisting of alcohol ethoxylates, alcohols, alkyl glycosides, alkyl polyglycosides, alkylphenol ethoxylates, amine oxides, block polymers, carboxylated alcohol or alkylphenol ethoxylates, carboxylic acids/fatty acids, cellulose derivatives, ethoxylated alcohols,... Agent: Allergan, Inc.

20070015692 - Cyclosporin compositions: A composition comprising a therapeutically effective amount of cyclosporin A, a blend of oils having a specific gravity of from 0.90 to 1.07, and a surfactant is disclosed herein.... Agent: Allergan, Inc.

20070015693 - Cyclosporin compositions: Cyclosporin A compositions are disclosed herein comprising an oil and a surfactant.... Agent: Allergan, Inc.

20070015694 - Cyclosporin compositions: A composition is disclosed herein comprising from about 0.001% to about 0.4% cyclosporin A, castor oil, and a surfactant selected from the group consisting of alcohol ethoxylates, alcohols, alkyl glycosides, alkyl polyglycosides, alkylphenol ethoxylates, amine oxides, block polymers, carboxylated alcohol or alkylphenol ethoxylates, carboxylic adds/fatty acids, cellulose derivatives, ethoxylated alcohols,... Agent: Allergan, Inc.

20070015696 - 621 human secreted proteins: The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating cancer and other hyperproliferative diseases and disorders. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and... Agent: Human Genome Sciences Inc Intellectual Property Dept.

20070015703 - Adamts13-containing compositions having thrombolytic activity: T